Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Cesarean Section in Primigravida

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

June 30, 2022

Conditions
Cesarean Section ComplicationsBlood Loss, SurgicalMisoprostolTranexamic Acid
Interventions
DRUG

Tranexamic acid

100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.

DRUG

Misoprostol 200mcg Tab

100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).

Trial Locations (1)

11562

faculty of medicine - Cairo university, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT04635007 - Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Cesarean Section in Primigravida | Biotech Hunter | Biotech Hunter